Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study | April 2018

Articles

American Journal of Psychiatry

https://ajp.psychiatryonline.org/doi/abs/10.1176/appi.ajp.2018.17060720

Effect of Esketamine Nasal Spray on Olfactory Function and Nasal Tolerability in Patients with Treatment-Resistant Depression: Results from Four Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Studies | July 2021

Articles

CNS Drugs

https://link.springer.com/article/10.1007/s40263-021-00826-9

Effect of Esketamine on Postoperative Depressive Symptoms in Patients Undergoing Thoracoscopic Lung Cancer Surgery: A Randomized Controlled Trial | March 2023

Articles

Frontiers in Psychiatry

https://www.frontiersin.org/articles/10.3389/fpsyt.2023.1128406/full

Effect of Esketamine on Postoperative Analgesia and Postoperative Delirium in Elderly Patients Undergoing Gastrointestinal Surgery | February 2024

Articles

BMC Anesthesiology

https://bmcanesthesiol.biomedcentral.com/articles/10.1186/s12871-024-02424-w

Phenomenology and Therapeutic Potential of Patient Experiences during Oral Esketamine Treatment for Treatment-Resistant Depression: An Interpretative Phenomenological Study | May 2023

Articles

Psychopharmacology

https://link.springer.com/article/10.1007/s00213-023-06388-6

Efficacy and Safety of Esketamine Nasal Spray in Patients with Treatment-Resistant Depression Who Completed a Second Induction Period: Analysis of the Ongoing SUSTAIN-3 Study | August 2023

Articles

CNS Drugs

https://link.springer.com/article/10.1007/s40263-023-01026-3

Meaningful Change in Depression Symptoms Assessed with the Patient Health Questionnaire (PHQ-9) and Montgomery-Asberg Depression Rating Scale (MADRS) among Patients with Treatment Resistant Depression in Two, Randomized, Double-Blind, Active-Controlled Trials of Esketamine Nasal Spray Combined with a New Oral Antidepressant | November 2020

Articles

Journal of Affective Disorders

https://www.sciencedirect.com/science/article/pii/S0165032720329967

Effects of Perioperative Use of Esketamine on Postpartum Depression Risk in Patients Undergoing Cesarean Section: A Randomized Controlled Trial | July 2023

Articles

Journal of Affective Disorders

https://www.sciencedirect.com/science/article/pii/S0165032723009539

Effects of Preoperative Nasal Spray Esketamine on Separation Anxiety and Emergence Agitation in Pediatric Strabismus Surgery: A Randomized Clinical Trial | December 2022

Articles

Medicine

https://www.doi.org/10.1097/MD.0000000000032280

Cardiac Safety of Esketamine Nasal Spray in Treatment-Resistant Depression: Results from the Clinical Development Program | January 2020

Articles

CNS Drugs

https://link.springer.com/article/10.1007/s40263-020-00699-4

Comparative Efficacy of Racemic Ketamine and Esketamine for Depression: A Systematic Review and Meta-Analysis | September 2020

Articles (Manuscripts-Versions)

PubMed Central>Journal of Affective Disorders

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7704936/

Evaluation of Ethnicity Effect on Intranasal Esketamine Pharmacokinetics by Population Pharmacokinetic Modeling Using Data from a Japanese Phase 2b Study | December 2022

Articles

Clinical Pharmacology in Drug Development

https://accp1.onlinelibrary.wiley.com/doi/10.1002/cpdd.1214

Efficacy and Safety of Racemic Ketamine and Esketamine for Depression: A Systematic Review and Meta-Analysis | March 2022

Articles (Manuscripts-Versions)

PubMed Central>Expert Opinion on Drug Safety

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9949988/

Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Plus a Newly Initiated Oral Antidepressant in Adult Patients with Treatment-Resistant Depression: A Randomized, Double-Blind, Multicenter, Active-Controlled Study Conducted in China and USA | March 2023

Articles

Neuropsychiatric Disease and Treatment

https://doi.org/10.2147/NDT.S391096

Case Report: Intramuscular Ketamine or Intranasal Esketamine as a Treatment in Four Patients with Major Depressive Disorder and Comorbid Anorexia Nervosa | May 2023

Articles

Frontiers in Psychiatry

https://www.frontiersin.org/articles/10.3389/fpsyt.2023.1181447/full

Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined with a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1) | July 2019

Articles

International Journal of Neuropsychopharmacology

https://doi.org/10.1093/ijnp/pyz039

Repeated, Low-Dose Oral Esketamine in Patients with Treatment-Resistant Depression: Pilot Study | December 2021

Articles

BJPsych Open

https://doi.org/10.1192/bjo.2021.1059

Metabolomic Signatures of Drug Response Phenotypes for Ketamine and Esketamine in Subjects with Refractory Major Depressive Disorder: New Mechanistic Insights for Rapid Acting Antidepressants | September 2016

Articles

Translational Psychiatry

https://www.nature.com/articles/tp2016145

Efficacy and Safety of Esketamine Nasal Spray Plus an Oral Antidepressant in Elderly Patients with Treatment-Resistant Depression- TRANSFORM-3 | October 2019

Articles

American Journal of Geriatric Psychiatry

https://www.sciencedirect.com/science/article/pii/S1064748119305330

Repeated Doses of Subcutaneous Esketamine in Patients with Treatment-Resistant Depression: Case Series in a General Hospital in Southern Brazil | April 2023

Articles

Psychiatry Research Case Reports

https://www.sciencedirect.com/science/article/pii/S2773021223000147

Repeated Subcutaneous Esketamine for Treatment-Resistant Depression: Impact of the Degree of Treatment Resistance and Anxiety Comorbidity | January 2021

Abstracts

Journal of Psychopharmacology

https://journals.sagepub.com/doi/abs/10.1177/0269881120978398

Esketamine vs Midazolam in Boosting the Efficacy of Oral Antidepressants for Major Depressive Disorder: A Pilot Randomized Clinical Trial | August 2023

Articles

JAMA Network Open

https://jamanetwork.com/article.aspx?doi=10.1001/jamanetworkopen.2023.28817

Intranasal Esketamine as Therapeutic Option: A Case Report of an Adolescent with Treatment Resistant Depression | June 2023

Articles

Frontiers in Psychiatry

https://www.frontiersin.org/articles/10.3389/fpsyt.2023.1118737/full

Predicting Outcome with Intranasal Esketamine Treatment: A Machine-Learning, Three-Month Study in Treatment-Resistant Depression (ESK-LEARNING) | July 2023

Articles

Psychiatry Research

https://www.sciencedirect.com/science/article/pii/S0165178123003281

Different Symptomatic Improvement Pattern Revealed by Factor Analysis between Placebo Response and Response to Esketamine in Treatment Resistant Depression | May 2022

Articles

Psychiatry and Clinical Neurosciences

https://onlinelibrary.wiley.com/doi/10.1111/pcn.13379

Characteristics of Real-World Commercially Insured Patients with Treatment-Resistant Depression Initiated on Esketamine Nasal Spray or Conventional Therapies in the United States | October 2022

Articles

Clinical Therapeutics

https://www.sciencedirect.com/science/article/pii/S0149291822003198

Esketamine in Treatment-Resistant Depression Patients Comorbid with Substance-Use Disorder: A Viewpoint on Its Safety and Effectiveness in a Subsample of Patients from the REAL-ESK Study | May 2023

Articles

European Neuropsychopharmacology

https://www.sciencedirect.com/science/article/pii/S0924977X23000779

Intranasal Esketamine Effectively Treats Treatment-Resistant Depression in Adults Regardless of Baseline Irritability | October 2022

Articles

Journal of Affective Disorders

https://www.sciencedirect.com/science/article/pii/S0165032722012113

Esketamine Nasal Spray for Rapid Reduction of Depressive Symptoms in Patients with Major Depressive Disorder Who Have Active Suicide Ideation with Intent: Results of a Phase 3, Double-Blind, Randomized Study (ASPIRE II) | August 2020

Articles

International Journal of Neuropsychopharmacology

https://doi.org/10.1093/ijnp/pyaa068

Investigating the Effectiveness and Tolerability of Intranasal Esketamine among Older Adults with Treatment-Resistant Depression (TRD): A Post-Hoc Analysis from the REAL-ESK Study Group | July 2023

Articles

American Journal of Geriatric Psychiatry

https://www.sciencedirect.com/science/article/pii/S1064748123003512

ICEBERG Study: An Indirect Adjusted Comparison Estimating the Long-Term Benefit of Esketamine Nasal Spray When Compared with Routine Treatment of Treatment Resistant Depression in General Psychiatry | October 2023

Articles

Frontiers in Psychiatry

https://www.frontiersin.org/articles/10.3389/fpsyt.2023.1250980/full

Esketamine for Unipolar Major Depression with Psychotic Features: A Retrospective Chart Review and Comparison with Nonpsychotic Depression | July 2022

Abstracts

Journal of Clinical Psychopharmacology

https://www.doi.org/10.1097/JCP.0000000000001571

The Effect of Low-Dose Esketamine on Postoperative Neurocognitive Dysfunction in Elderly Patients Undergoing General Anesthesia for Gastrointestinal Tumors: A Randomized Controlled Trial | June 2023

Articles

Drug Design, Development and Therapy

https://doi.org/10.2147/DDDT.S406568

Self-Reported Review of the Value of Esketamine in Patients with Treatment-Resistant Depression: Understanding the Patient Experience in the STRIVE Study | August 2020

Articles

Psychiatry Research

https://www.sciencedirect.com/science/article/pii/S016517812030158X

Repeated Intravenous Esketamine Treatment in Patients with ECT-Resistant Major Depressive Disorder | August 2022

Articles

Journal of Affective Disorders Reports

https://www.sciencedirect.com/science/article/pii/S2666915322000920

Esketamine: A New Paradigm for Treatment-Resistant Depression | April 2019

Multimedia (Lectures-Conferences)

University of Connecticut

http://mediasite.uchc.edu/mediasite41/Play/ae2eb664302f4c37b470d6c2f3bc85611d

Extended Applications the Subcutaneous Esketamine for Major Depression with Suicidal Ideation in Autism Traits-Case Report | December 2022

Articles

Psychiatry Research Case Reports

https://www.sciencedirect.com/science/article/pii/S277302122200089X

Cost-Per-Remitter with Esketamine Nasal Spray versus Standard of Care for Treatment-Resistant Depression | February 2021

Articles

Journal of Comparative Effectiveness Research

https://doi.org/10.2217/cer-2020-0276

The Incidental Resolution of Severe Alcohol Use Disorder during Esketamine Treatment of Major Depressive Disorder: A Case Report | December 2022

Articles

Case Reports in Psychiatry

https://www.hindawi.com/journals/crips/2022/8992697/

Listening to Music during Intranasal (Es)Ketamine Therapy in Patients with Treatment-Resistant Depression Correlates with Better Tolerability and Reduced Anxiety | January 2024

Articles

Frontiers in Psychiatry

https://www.frontiersin.org/articles/10.3389/fpsyt.2024.1327598/full

Therapeutic Potentials of Ketamine and Esketamine in Obsessive-Compulsive Disorder (OCD), Substance Use Disorders (SUD) and Eating Disorders (ED): A Review of the Current Literature | June 2021

Articles

Brain Sciences

https://www.mdpi.com/2076-3425/11/7/856

Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial | February 2018

Articles

JAMA Psychiatry

https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2666767

Acute Effects of Intravenous Sub-Anesthetic Doses of Ketamine and Intranasal Inhaled Esketamine on Suicidal Ideation: A Systematic Review and Meta-Analysis | March 2023

Articles

Neuropsychiatric Disease and Treatment

https://doi.org/10.2147/NDT.S401032

Comparison of Long-Term Efficacy and Safety of Esketamine Nasal Spray Plus Oral Antidepressant in Younger versus Older Patients with Treatment-Resistant Depression: Post-Hoc Analysis of SUSTAIN-2, a Long-Term Open-Label Phase 3 Safety and Efficacy Study | October 2021

Articles

American Journal of Geriatric Psychiatry

https://www.sciencedirect.com/science/article/pii/S1064748121004917

At Baseline Patients Treated with Esketamine Have Higher Burden of Disease than Other Patients with Treatment Resistant Depression: Learnings from a Population Based Study | January 2021

Articles

Depression and Anxiety

https://onlinelibrary.wiley.com/doi/10.1002/da.23138

Adverse Effects of Esketamine for the Treatment of Major Depression Disorder: Findings from Randomized Controlled Trials | January 2021

Articles

Psychiatric Quarterly

https://link.springer.com/article/10.1007/s11126-020-09871-x

Repeated Oral Esketamine in Patients with Treatment Resistant Depression and Comorbid Posttraumatic Stress Disorder | May 2023

Articles

Heliyon

https://www.sciencedirect.com/science/article/pii/S2405844023030906

Intranasal Esketamine as Tool for Rapid Cycling Bipolar Disorder: A Case Report of Successful Mood Stabilization | October 2023

Articles

Psychiatry Research Case Reports

https://www.sciencedirect.com/science/article/pii/S277302122300086X

The Use of Esketamine in the Treatment of Patients with Severe Depression and Suicidal Ideation: Systematic Review and Meta-Analysis | May 2023

Articles

Revista da Associacao Medica Brasileira

https://doi.org/10.1590/1806-9282.2023D694

Key Considerations for the Use of Ketamine and Esketamine for the Treatment of Depression: Focusing on Administration, Safety, and Tolerability | April 2022

Articles (Manuscripts-Versions)

PubMed Central>Expert Opinion on Drug Safety

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9308739/